Report of Foreign Issuer (6-k)
February 05 2020 - 3:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to
Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February, 2020
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into
English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jeusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On
February 5, 2020, BiondVax Pharmaceuticals Ltd. issued a press release announcing that preliminary data from the NIH/NIAID-sponsored
Phase 2 clinical trial of BiondVax’s M-001 universal influenza vaccine candidate validates results of previous clinical Trials.
A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
Exhibits 99.1 of this
Report on Form 6-K are hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration No.
333-201283).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: February 5, 2020
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Sep 2023 to Sep 2024